Dustin Ruff

1.5k total citations · 1 hit paper
36 papers, 1.0k citations indexed

About

Dustin Ruff is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, Dustin Ruff has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 6 papers in Pharmacology and 6 papers in Cognitive Neuroscience. Recurrent topics in Dustin Ruff's work include Migraine and Headache Studies (15 papers), Attention Deficit Hyperactivity Disorder (12 papers) and Psychosomatic Disorders and Their Treatments (4 papers). Dustin Ruff is often cited by papers focused on Migraine and Headache Studies (15 papers), Attention Deficit Hyperactivity Disorder (12 papers) and Psychosomatic Disorders and Their Treatments (4 papers). Dustin Ruff collaborates with scholars based in United States, United Kingdom and Germany. Dustin Ruff's co-authors include David Michelson, Albert J. Allen, Jeffrey H. Newcorn, Christopher J. Kratochvil, Rodney J. Moore, Charles D. Casat, Sheena K. Aurora, Eric Pearlman, James T. McCracken and Shuyu Zhang and has published in prestigious journals such as Journal of the American College of Cardiology, American Journal of Psychiatry and Neurology.

In The Last Decade

Dustin Ruff

35 papers receiving 980 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

2024 63 citations Christopher M. Kramer, Barry A. Borlaug et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dustin Ruff United States	18	881	262	167	159	117	36	1.0k
Lawrence Ginsberg United States	17	539 0.6×	303 1.2×	75 0.4×	110 0.7×	122 1.0×	38	873
Lefteris Lykouras Greece	15	388 0.4×	273 1.0×	32 0.2×	280 1.8×	91 0.8×	54	947
Clemens Bauer United States	17	103 0.1×	310 1.2×	55 0.3×	218 1.4×	24 0.2×	70	884
Xiaoping Ning United States	12	823 0.9×	83 0.3×	469 2.8×	66 0.4×	23 0.2×	48	887
Cristelle Rodriguez Switzerland	17	330 0.4×	448 1.7×	18 0.1×	31 0.2×	44 0.4×	55	953
Emilie T. Reas United States	18	274 0.3×	235 0.9×	42 0.3×	20 0.1×	15 0.1×	42	788
Carl Eckerström Sweden	21	610 0.7×	210 0.8×	25 0.1×	19 0.1×	18 0.2×	40	1.0k
S. Bakchine France	14	210 0.2×	150 0.6×	43 0.3×	23 0.1×	84 0.7×	37	719
Lauren Nutile United States	6	166 0.2×	238 0.9×	60 0.4×	38 0.2×	87 0.7×	9	567
Diana Kadetoff Sweden	14	522 0.6×	209 0.8×	27 0.2×	180 1.1×	448 3.8×	19	1.0k

Countries citing papers authored by Dustin Ruff

Since Specialization

Citations

This map shows the geographic impact of Dustin Ruff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dustin Ruff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dustin Ruff more than expected).

Fields of papers citing papers by Dustin Ruff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dustin Ruff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dustin Ruff. The network helps show where Dustin Ruff may publish in the future.

Co-authorship network of co-authors of Dustin Ruff

This figure shows the co-authorship network connecting the top 25 collaborators of Dustin Ruff. A scholar is included among the top collaborators of Dustin Ruff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dustin Ruff. Dustin Ruff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoffman, Sarah R., et al.. (2024). Monitoring Pregnancies Exposed to Galcanezumab for Migraine in a United States Administrative Claims Database. Pharmacoepidemiology and Drug Safety. 33(10). e70015–e70015.

Kramer, Christopher M., Barry A. Borlaug, Dustin Ruff, et al.. (2024). Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure. Journal of the American College of Cardiology. 85(7). 699–706. 63 indexed citations breakdown →

Seng, Elizabeth K., Christian Lampl, Lars Viktrup, et al.. (2024). Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb). Pain and Therapy. 13(6). 1589–1615. 2 indexed citations

Andreou, Anna P., Peter Wright, Holland C. Detke, Dustin Ruff, & Uwe Reuter. (2020). Galcanezumab Shows Efficacy as Early as Day 1 After Initial Treatment vs. Placebo for the Prevention of Episodic and Chronic Migraine (4014). Neurology. 94(15_supplement). 1 indexed citations

Vargas, Bert B., Delphine Magis, Erin Doty, et al.. (2020). Assessment to Identify Predictors of 2-Hour Pain Freedom among Patients Enrolled in 2 Phase 3 Studies of Lasmiditan for Acute Treatment of Migraine (1763). Neurology. 94(15_supplement). 1 indexed citations

Lipton, Richard B., Louise Lombard, Dustin Ruff, et al.. (2020). Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. The Journal of Headache and Pain. 21(1). 20–20. 30 indexed citations

Ford, Janet H., Russell Nichols, Shonda A. Foster, et al.. (2019). Galcanezumab Significantly Reduced Health Care Resource Utilization and Acute Medication Use in Patients with Chronic Migraine: Findings from a Phase 3, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension (P1.10-001). Neurology. 92(15_supplement). 1 indexed citations

Ford, Janet H., Shonda A. Foster, Virginia L. Stauffer, et al.. (2018). Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. Patient Preference and Adherence. Volume 12. 2413–2424. 23 indexed citations

Li, Hu, et al.. (2017). Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure. Urology. 105. 76–84. 11 indexed citations

10.

Clemow, David B., Elias Sarkis, Dustin Ruff, et al.. (2015). Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. Expert Review of Neurotherapeutics. 15(11). 1353–1366. 3 indexed citations

11.

Williamson, Owen D., et al.. (2014). Onset of Response with Duloxetine Treatment in Patients with Osteoarthritis Knee Pain and Chronic Low Back Pain: A Post Hoc Analysis of Placebo-Controlled Trials. Clinical Therapeutics. 36(4). 544–551. 11 indexed citations

12.

Oelke, Matthias, Jeffrey P. Weiss, Charalampos Mamoulakis, et al.. (2014). Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World Journal of Urology. 32(5). 1127–1132. 27 indexed citations

13.

Wietecha, Linda, Dustin Ruff, Albert J. Allen, Laurence L. Greenhill, & Jeffrey H. Newcorn. (2013). Atomoxetine Tolerability in Pediatric and Adult Patients Receiving Different Dosing Strategies. The Journal of Clinical Psychiatry. 74(12). 1217–1223. 16 indexed citations

14.

Camporeale, Angelo, et al.. (2013). Profile of Sexual and Genitourinary Treatment-Emergent Adverse Events Associated with Atomoxetine Treatment: A Pooled Analysis. Drug Safety. 36(8). 663–671. 18 indexed citations

15.

Wietecha, Linda, Joel Young, Dustin Ruff, et al.. (2012). Atomoxetine Once Daily for 24 Weeks in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). Clinical Neuropharmacology. 35(3). 125–133. 16 indexed citations

16.

Spencer, Thomas, Christopher J. Kratochvil, R. Bart Sangal, et al.. (2007). Effects of Atomoxetine on Growth in Children with Attention-Deficit/Hyperactivity Disorder Following up to Five Years of Treatment. Journal of Child and Adolescent Psychopharmacology. 17(5). 689–699. 50 indexed citations

17.

Kratochvil, Christopher J., David Michelson, Jeffrey H. Newcorn, et al.. (2007). High-Dose Atomoxetine Treatment of ADHD in Youths With Limited Response to Standard Doses. Journal of the American Academy of Child & Adolescent Psychiatry. 46(9). 1128–1137. 28 indexed citations

18.

Michelson, David, Holly A. Read, Dustin Ruff, et al.. (2007). CYP2D6 and Clinical Response to Atomoxetine in Children and Adolescents With ADHD. Journal of the American Academy of Child & Adolescent Psychiatry. 46(2). 242–251. 118 indexed citations

19.

Carlson, Gabrielle A., David Dunn, Douglas K. Kelsey, et al.. (2007). A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatry and Mental Health. 1(1). 10–10. 40 indexed citations

20.

Ruff, Dustin, et al.. (1998). Mobility of General Managers as Lodging Size, Service Vary. Florida International University Digital Commons (Florida International University). 16(2). 5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact